

|  |  |   |
|--|--|---|
| <b>Statement of Deficiencies</b>   | <b>(X1) Provider/Supplier/CLIA Identification Number</b><br>45D0976266   | <b>(X3) Date Survey Completed</b><br>08/05/2021 |
| <b>Name of Provider or Supplier</b><br>East Texas Border Health Clinic   | <b>Street Address, City, State</b><br>1011 S William Street, Atlanta, TX |   |
| For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency. |  |   |

| <b>(X4) ID Prefix Tag</b> | <b>Summary Statement of Deficiencies</b>   |
|---------------------------|--|
| <b>D0000</b>              | Based on a proficiency testing desk review survey performed on April 12, 2021 and August 5, 2021, the laboratory was found to be out of compliance based on the following CONDITION LEVEL DEFICIENCIES: D2016 - 42 C.F.R. 493.803 Condition: Successful participation D2017 - 42 C.F.R. 493.807 Condition: Reinstatement of laboratories performing non-waived testing D6000 - 42 C.F.R. 493.1403 Condition: Laboratory Director, moderate complexity  |
| <b>D2016</b>              | <p><b>SUCCESSFUL PARTICIPATION</b><br/>CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by:<br/>Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Proficiency</p> |

|                     |   |
|---------------------|---|
|                     | <p>Institute proficiency testing records, the facility failed to achieve successful performance in five of five consecutive testing events for the analyte Digoxin, resulting in unsuccessful participation in the specialty of Toxicology. Refer to D2118 and D2119.</p>   |
| <p><b>D2017</b></p> | <p><b>REINSTATEMENT OF NONWAIVED LABORATORIES</b><br/>CFR(s): 493.807(a)(b)</p> <p>(a) If a laboratory's certificate is suspended or limited or its Medicare or Medicaid approval is cancelled or its Medicare or Medicaid payments are suspended because it fails to participate successfully in proficiency testing for one or more specialties, subspecialties, analyte or test, or voluntarily withdraws its certification under CLIA for the failed specialty, subspecialty, or analyte, the laboratory must then demonstrate sustained satisfactory performance on two consecutive proficiency testing events, one of which may be on site, before CMS will consider it for reinstatement for certification and Medicare or Medicaid approval in that specialty, subspecialty, analyte or test. (b) The cancellation period for Medicare and Medicaid approval or period for suspension of Medicare or Medicaid payments or suspension or limitation of certification under CLIA for the failed specialty, subspecialty, or analyte or test is for a period of not less than six months from the date of cancellation, limitation or suspension of the CLIA certificate.</p> <p>This CONDITION is not met as evidenced by:<br/>Based on desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Proficiency Institute (API) proficiency testing records, the facility failed to achieve successful performance in five of five consecutive testing events for the analyte Digoxin, resulting in a non-initial proficiency testing failure in the specialty of Toxicology. The findings included: 1. Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and the American Proficiency Institute (API) Comparative Evaluations, the laboratory received the following unsatisfactory scores (satisfactory is 80% or greater) for the analyte Digoxin in the specialty of Toxicology in five of five consecutive events: 2020 API 1st event - Digoxin 60% 2020 API 2nd event- Digoxin 0% 2020 API 3rd event- Digoxin 40% 2021 API 1st event - Digoxin 60% 2021 API 2nd event - Digoxin 20% 2. Based on review of the American Proficiency Institute (API) Comparative Evaluations, the facility failed to achieve an overall testing event score for Toxicology in five of five consecutive testing events in 2020 and 2021. 2020 API 1st event - Toxicology 60% 2020 API 2nd event- Toxicology 0% 2020 API 3rd event- Toxicology 40% 2021 API 1st event - Toxicology 60% 2021 API 2nd event - Toxicology 20%</p> |
| <p><b>D2109</b></p> | <p><b>TOXICOLOGY</b><br/>CFR(s): 493.845(a)</p> <p>Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event.</p> <p>This STANDARD is not met as evidenced by:<br/>Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and the American Proficiency</p>   |

|                     |  |
|---------------------|--|
|                     | <p>Institute (API) Comparative Evaluations, the facility failed to attain a score of at least 80 percent for the analyte Digoxin in five of five consecutive testing events in 2020 and 2021. The findings included: 1. Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile, the laboratory received the following unsatisfactory scores (satisfactory is 80% or greater) for the analyte Digoxin in the specialty of Toxicology in five of five consecutive events: 2020 API 1st event - Digoxin 60% 2020 API 2nd event- Digoxin 0% 2020 API 3rd event- Digoxin 40% 2021 API 1st event - Digoxin 60% 2021 API 2nd event - Digoxin 20%</p>   |
| <p><b>D2110</b></p> | <p><b>TOXICOLOGY</b><br/>CFR(s): 493.845(b)</p> <p>Failure to attain an overall testing event score of at least 80 percent is unsatisfactory performance.</p> <p>This STANDARD is not met as evidenced by:<br/>Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and the American Proficiency Institute (API) Comparative Evaluations, the facility failed to attain an overall testing event score of at least 80 percent for the specialty of Toxicology in five of five consecutive testing events in 2020 and 2021. The findings included: 1. Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile, the laboratory received the following unsatisfactory scores (satisfactory is 80% or greater) for the analyte Digoxin in the specialty of Toxicology in five of five consecutive events: 2020 API 1st event - Toxicology 60% 2020 API 2nd event- Toxicology 0% 2020 API 3rd event- Toxicology 40% 2021 API 1st event - Toxicology 60% 2021 API 2nd event - Toxicology 20%</p>                              |
| <p><b>D2118</b></p> | <p><b>TOXICOLOGY</b><br/>CFR(s): 493.845(f)</p> <p>Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by:<br/>Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and the American Proficiency Institute (API) Comparative Evaluations, the facility failed to achieve satisfactory performance for the analyte Digoxin in five of five consecutive testing events in 2020 and 2021. The findings included: 1. Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile, the laboratory received the following unsatisfactory scores (satisfactory is 80% or greater) for the analyte Digoxin in the specialty of Toxicology in five of five consecutive events: 2020 API 1st event - Digoxin 60% 2020 API 2nd event- Digoxin 0% 2020 API 3rd event- Digoxin 40% 2021 API 1st event - Digoxin 60% 2021 API 2nd event - Digoxin 20%</p> |
| <p><b>D2119</b></p> | <p><b>TOXICOLOGY</b></p>   |

CFR(s): 493.845(g)

Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and the American Proficiency Institute (API) Comparative Evaluations, the facility failed to achieve an overall testing event score of satisfactory performance for Toxicology in five of five consecutive testing events in 2020 and 2021. The findings included: 1. Based on review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile, the laboratory received the following unsatisfactory scores (satisfactory is 80% or greater) for the analyte Digoxin in the specialty of Toxicology in five of five consecutive events: 2020 API 1st event - Toxicology 60% 2020 API 2nd event- Toxicology 0% 2020 API 3rd event- Toxicology 40% 2021 API 1st event - Toxicology 60% 2021 API 2nd event - Toxicology 20%

**D6000**

**MODERATE COMPLEXITY LABORATORY DIRECTOR**

CFR(s): 493.1403

The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.

This CONDITION is not met as evidenced by:

Based on desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Proficiency Institute (API) proficiency testing records, the laboratory director failed to ensure successful participation in a HHS approved proficiency testing program for analyte Digoxin and the specialty of Toxicology. Refer to D6016.

**D6016**

**LABORATORY DIRECTOR RESPONSIBILITIES**

CFR(s): 493.1407(e)(4)(i)

The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:

Based on desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) Report 155 Individual Laboratory Profile and American Proficiency Institute (API) proficiency testing records, the laboratory director failed to ensure successful participation in a HHS approved proficiency testing program for analyte Digoxin in the specialty Toxicology. Refer to D2118 and D2119.